GAINERS 1. Infinity Pharmaceuticals Inc. (INFI) Gained 123.35% to close Thursday's (Oct.12) trading at $3.73. News: The Company will be reporting clinical and translational data from monotherapy dose-escalation component of its ongoing …
Register for free on Stock-Callers.com and download the latest research report on INFI at: http://stock …
Claim your 2-week free trial to StreetInsider Premium here. Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits …
Investors are likely punishing INFI's stock price, knowing that each delay pushes ... This is one of a few articles in a series by David Phillips highlighting "Drugs that Disappointed Investors in 2013," and what we can learn from the ride.
It may not reach its all-time highs any time soon, but even getting half its zenith would be a major boon for VRX stock. Another name among hard-hit pharma stocks is Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Already flirting with …
Admittedly, INFI stock is extremely speculative. Nevertheless, a little bit of positive news could go a long way for Infinity. …
Infinity is an ideal candidate for a short sale. Infinity Pharmaceuticals (NASDAQ:INFI) has a short interest of 8%, which shows the generally positive mood on the Street for this stock. Despite the recent P2 failure of IPI-145 for RA, and its …
CAMBRIDGE - Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2018 financial ... The decrease in G&A expense was primarily due to a reduction in bonus and stock compensation. Infinity's 2018 financial …
Lululemon Athletica Inc (LULU): LULU stock is up 4.94% today. Infinity Pharmaceuticals (INFI): INFI stock is down 2.68% today. Auris Medical Holding Ag (EARS): EARS stock is up 3.27% today. Milacron Holdings Corp (MCRN): MCRN …